Claude

What's Next

Centene's next 90 days hinge on a single data point: the Q1 2026 health benefits ratio, which will be reported on April 28, 2026. Every other catalyst is secondary.

No Results

**April 28 is the binary event.** Analysts expect Q1 EPS of $1.88 on roughly $47B revenue. The HBR is the only number that matters. If it comes in below 90%, the corrective pricing is working and the path to $3+ full-year EPS is credible. If it is above 91%, the re-pricing failed and the stock likely revisits its $25 low.

The CMS finalization of a 2.48% Medicare Advantage rate increase for 2027 is a genuine tailwind – it exceeds the advance notice estimate and signals continued federal support for the MA program. This directly benefits Centene's Medicare segment, which was the only segment to grow gross margin in FY2025.

The OBBBA overhang is real but delayed. Work requirements for Medicaid expansion adults do not begin until January 2027, giving Centene roughly 9 months of runway before membership attrition accelerates. The market is pricing this risk now, but the actual financial impact will not show up until mid-2027.

LEAPS / Options

**Options data is not actionable.** The LEAPS summary was generated with a current price estimate of $20.00 -- roughly 46% below the actual stock price of $37.28. All available strikes ($17.50, $20.00, $22.50) are deeply in-the-money at the current price, making the greeks, implied volatilities, and payoff analysis unreliable. No specific contract recommendations can be made from this data.

The Jan 2028 LEAPS chain does exist with moderate open interest (376 contracts at the $20 strike), confirming institutional positioning. However, without current pricing at strikes relevant to the $37 stock price (the $35-$45 range), no actionable analysis is possible.

For investors seeking leveraged exposure to the HBR recovery thesis: Consider looking at Jan 2028 calls in the $35-$45 strike range using live broker data. The approximately 62% implied volatility in the stale data suggests the options market is pricing significant uncertainty – appropriate given the binary April 28 catalyst. Post-earnings, IV should compress, making pre-earnings options purchases expensive.

Options verdict: No actionable setup from available data. Revisit after April 28 earnings when both the fundamental picture and options pricing will be more informative.